Stifel analyst Benjamin Burnett lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $103.00 (from $120.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Beam Therapeutics Inc (BEAM) PT Lowered to $60 at RBC CapitalNovember 7, 2022 10:51 AM Form 10-Q Beam Therapeutics Inc. For: Sep 30November 7, 2022 7:35 AM Form 8-K Beam Therapeutics Inc. For: Nov 07November 7, 2022 7:01 AM Beam, Inc. (BEAM) Misses Q3 EPS by 28c, Revenues BeatsNovember 7, 2022 6:32 AM Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial ResultsNovember 7, 2022 6:30 AM Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results November 7, 2022 6:30 AM Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual MeetingNovember 3, 2022 9:01 AM Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual MeetingNovember 3, 2022 9:01 AM